ATEZOLIZUMAB PLUS VEMURAFENIB AND COBIMETINIB PROVIDES FAVORABLE SURVIVAL OUTCOMES IN PATIENTS WITH HIGH TUMOR MUTATION BURDEN AND PROINFLAMMATORY GENE SIGNATURE IN THE PHASE 3 IMSPIRE150 STUDY

Simple item page
dc.contributor.authorLewis, Karl
dc.contributor.authorAscierto, Paolo
dc.contributor.authorRobert, Caroline
dc.contributor.authorMunhoz, Rodrigo
dc.contributor.authorLiszkay, Gabriella
dc.contributor.authorDe La Cruz Marino, Luis
dc.contributor.authorOlah, Judit
dc.contributor.authorQueirolo, Paola
dc.contributor.authorMackiewicz, Jacek
dc.contributor.authorShah, Kalpit
dc.contributor.authorForbes, Harper
dc.contributor.authorHertig, Christian
dc.contributor.authorYan, Yibing
dc.contributor.authorGutzmer, Ralf
dc.contributor.authorMcArthur, Grant
dc.contributor.authoraffiliation[Lewis, Karl] Univ Colorado Comp Canc Ctr, Aurora, CO USA
dc.contributor.authoraffiliation[Ascierto, Paolo] Ist Nazl Tumori IRCCS, Naples, Italy
dc.contributor.authoraffiliation[Robert, Caroline] Gustave Roussy, Villejuif, France
dc.contributor.authoraffiliation[Robert, Caroline] Univ Paris Sad, Paris, France
dc.contributor.authoraffiliation[Munhoz, Rodrigo] Inst Canc Estado, Sao Paulo, Brazil
dc.contributor.authoraffiliation[Liszkay, Gabriella] Orszagos Onkol Int, Budapest, Hungary
dc.contributor.authoraffiliation[De La Cruz Marino, Luis] Hosp Univ Virgen Macarena, Seville, Spain
dc.contributor.authoraffiliation[Olah, Judit] Univ Szeged Szent Gyorgyi, Szeged, Hungary
dc.contributor.authoraffiliation[Queirolo, Paola] IRCCS Ist Europeo Oncol, Milan, Italy
dc.contributor.authoraffiliation[Mackiewicz, Jacek] Greater Poland Canc Ctr, Poznan, Poland
dc.contributor.authoraffiliation[Shah, Kalpit] Genentech Inc, San Francisco, CA 94080 USA
dc.contributor.authoraffiliation[Yan, Yibing] Genentech Inc, San Francisco, CA 94080 USA
dc.contributor.authoraffiliation[Forbes, Harper] F Hoffmann La Roche Ltd, Mississauga, ON, Canada
dc.contributor.authoraffiliation[Hertig, Christian] F Hoffmann La Roche Ltd, Mississauga, ON, Canada
dc.contributor.authoraffiliation[Gutzmer, Ralf] Haut Tumour Zentrum Hannover HTZH, Hannover, Germany
dc.contributor.authoraffiliation[McArthur, Grant] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
dc.date.accessioned2025-01-07T16:02:39Z
dc.date.available2025-01-07T16:02:39Z
dc.date.issued2020-11-01
dc.identifier.doi10.1136/jitc-2020-SITC2020.0307
dc.identifier.essn2051-1426
dc.identifier.unpaywallURLhttps://jitc.bmj.com/content/jitc/8/Suppl_3/A188.2.full.pdf
dc.identifier.urihttps://hdl.handle.net/10668/27584
dc.identifier.wosID616665300299
dc.issue.number3
dc.journal.titleJournal for immunotherapy of cancer
dc.journal.titleabbreviationJ. immunother. cancer
dc.language.isoen
dc.organizationSAS - Hospital Universitario Virgen del Rocío
dc.organizationSAS - Hospital Universitario Virgen Macarena
dc.page.numberA188-A189
dc.publisherBmj publishing group
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.titleATEZOLIZUMAB PLUS VEMURAFENIB AND COBIMETINIB PROVIDES FAVORABLE SURVIVAL OUTCOMES IN PATIENTS WITH HIGH TUMOR MUTATION BURDEN AND PROINFLAMMATORY GENE SIGNATURE IN THE PHASE 3 IMSPIRE150 STUDY
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number8
dc.wostypeMeeting Abstract

Files

Collections

SAS - Hospital Universitario Virgen del Rocío
SAS - Hospital Universitario Virgen Macarena

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía